Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Gastric, Pancreatic, and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CLDN18.2 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Isoform-Specific Antigen | CLDN18.2 ECD-Fc Protein (HEK293, >95% purity, selective over CLDN18.1) | View CLDN18.2 Products |
| Full-Length Gene Delivery | CLDN18.2 Lentivirus Premade Particles for stable cell line generation (preserves native tetraspanin conformation) | View CLDN18.2 Products |
| Isoform Counter-Screen | CLDN18.1 Full-Length Protein (for selectivity assays, endotoxin <1 EU/µg) | View CLDN18.1 Products |
| Benchmark Antibody | Anti-CLDN18.2 (Zolbetuximab Biosimilar) – recombinant positive control, sequence verified | View CLDN18.2 Products |
| Validation Tool | CLDN18.2 siRNA Set (knockdown verification and specificity confirmation) | View CLDN18.2 Products |
| Homology Control (Claudin Family) | CLDN6 and CLDN9 proteins (for cross-reactivity and off-target liability assessment) | View CLDN6 Products, View CLDN9 Products |
| Related Target for Bispecifics | CD3E (essential for CLDN18.2×CD3 T-cell engager validation) | View CD3E Products |
| Related Target for CAR-T | 4-1BB (co-stimulatory domain critical for CAR-T engineering) | View 4-1BB Products |
| Related Target for Combination | HER2 (gastric cancer standard, expression often mutually exclusive with CLDN18.2) | View HER2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CLDN18.1 vs CLDN18.2 Isoform Selectivity | Matched pair of CLDN18.1 and CLDN18.2 proteins (>95% purity) for orthogonal counter-screening |
| Native Tetraspanin Conformation / Multi-pass TM loss | Lentivirus-based stable cell lines (HEK293 background) preserving full-length native folding |
| Cross-Claudin Specificity (CLDN6/9) | Homology panel (CLDN6, CLDN9) included for off-target screening |
| Lack of Reliable Positive Controls | Clinical benchmark antibody (Zolbetuximab biosimilar) provided for assay calibration |
| ADC Internalization Validation | CLDN18.2 stable cell lines compatible with pH-sensitive dye internalization assays |
| False Positives in Flow Cytometry | Validated siRNA for target-specific knockdown confirmation |
| Cross-Species Evaluation (Cyno/Mouse) | Human/Cynomolgus/Mouse CLDN18.2 ortholog proteins available |
| Tight Junction Accessibility | Soluble ECD proteins for epitope mapping independent of junctional barriers |
Live CLDN18.2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLDN18.2 therapeutics has entered a commercialization phase following the first-mover approval of Astellas' Zolbetuximab (Vyloy) for gastric cancer. The landscape is rapidly diversifying beyond monoclonal antibodies into next-generation modalities including antibody-drug conjugates (ADCs), bispecific T-cell engagers, and CAR-T cell therapies. The next wave of R&D focuses on isoform-selective epitopes (CLDN18.2 vs CLDN18.1) to avoid pulmonary toxicity, improved solid-tumor penetration, and rational combination regimens with immune checkpoint inhibitors. Major players such as Daiichi Sankyo, AstraZeneca, BioNTech, Amgen, and CARsgen are actively competing in this space. Zolbetuximab's clinical validation has confirmed CLDN18.2 as a druggable target in approximately 30–40% of gastric cancer patients with high expression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Astellas (Vyloy), Transcenta | Gastric/GEJ Adenocarcinoma | Isoform Selectivity (CLDN18.2 vs CLDN18.1 distinct ECD proteins) |
| Antibody-Drug Conjugate (ADC) | Daiichi Sankyo (DS-9606a), BioNTech (BNT141), AstraZeneca (AZD0901), Elevation Oncology (EO-3021) | Gastric, Pancreatic, Advanced Solid Tumors | Internalization Assay (high-purity stable cell lines expressing native CLDN18.2) |
| Bispecific T-cell Engager | Amgen (AMG 910), BioNTech (BNT142), Astellas, Akesobio (AK138D) | HER2-negative gastric, Solid Tumors | Isoform Selectivity Panel + CD3 heterodimer validation |
| CAR-T Cell Therapy | CARsgen (CT041), Legend Biotech (LB1908) | Refractory Gastric, Pancreatic Cancer | Cell-based cytotoxicity (Lentivirus stable lines with endogenous-like expression) |
Key Mutation and Genomic Variant
- dbSNP rs17204075 (UniProt P56856 VAR_033775): A validated mutation in CLDN18. This variant may affect protein structure or expression, and its relevance to drug resistance or isoform selectivity is under investigation. When designing CLDN18.2-targeted therapeutics, consider evaluating binding affinity against cells expressing this variant to ensure broad coverage.
Future Outlook and Commercial Implications
The next 3–5 years will see CLDN18.2 therapies move from later-line to first-line settings and expand into pancreatic cancer. Combination with immune checkpoint inhibitors will become standard. Resistance mechanisms involving epitope loss or mutation will drive demand for CLDN18.2 mutant proteins and second-generation molecules. Diagnostic standardization (IHC cut-off) and subcutaneous formulations represent key differentiation opportunities. TarMart's full suite of reagents, from isoform-selective proteins and lentivirus particles to benchmark antibodies and related target panels, supports every stage of this evolving landscape.